daraxonrasib

New reporting examines why daraxonrasib, a breakthrough drug for pancreatic cancer, eventually stops working in patients. Researchers have identified clues about the resistance mechanisms that develop over time, a step that could guide combination treatments and extend the drug's effectiveness for one of the deadliest cancers.